Third-Party Tested ≥98% HPLC Purity — USA Shipped

Tissue Repair Research Guide

Wolverine Blend (TB-500 + BPC-157): Mechanism, Handling & Research Guide

Also known as: Wolverine Blend, Wolverine stack, TB-500 + BPC-157 blend, BPC-157 TB-500 stack, Wolverine peptide blend

Key Facts

Wolverine Blend (TB-500 + BPC-157) is a tissue repair research peptide. Dual-peptide recovery stack combining BPC-157 and TB-500 for accelerated tissue repair research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification multi-peptide blend (BPC-157 + TB-500/thymosin beta-4) for tissue-repair research
Research Half-Life Varies by component and not well characterized for the blend; BPC-157 and TB-500/thymosin beta-4 are reported on the order of roughly minutes to a few hours in animal-model studies, and no combined-formulation pharmacokinetics have been published.
Form Lyophilized powder
Research Category Tissue Repair

What is Wolverine Blend (TB-500 + BPC-157)?

The Wolverine stack is a dual-peptide research blend combining BPC-157 (10mg) and TB-500/Thymosin Beta-4 (10mg) in a single vial for convenience in tissue repair and recovery studies. The rationale for this combination lies in the complementary mechanisms of action: BPC-157 primarily upregulates VEGF and FGF to promote localized angiogenesis and tendon/GI repair through the FAK-paxillin pathway, while TB-500 promotes systemic cell migration through G-actin sequestration and laminin-5 expression. Together, research suggests these peptides may address both the localized inflammatory response and the broader tissue remodeling cascade simultaneously. Preclinical animal studies on each individual component are extensive -- BPC-157 has been studied in over 100 published papers from the Sikiric laboratory at the University of Zagreb, while TB-500 has a robust literature base in dermal, cardiac, and musculoskeletal repair models. The combined approach is informed by research principles suggesting that multi-pathway activation in wound healing (angiogenesis plus cell migration plus anti-inflammation) may produce outcomes beyond what either peptide achieves alone. No published clinical trials exist specifically on the BPC-157/TB-500 combination in humans; the research basis is extrapolated from individual component studies. Store lyophilized powder at -20C; reconstitute with 2mL bacteriostatic water and refrigerate at 2-8C for up to 14 days. This combination is popular among sports medicine research labs, orthopedic research institutions, and post-surgical recovery research programs.

Wolverine Blend (TB-500 + BPC-157) Research Applications

In published and preclinical research, Wolverine Blend (TB-500 + BPC-157) has been studied across the following areas:

  • Rapid tendon, ligament, and muscle repair
  • Inflammation-pathway research
  • Tissue-repair models
  • Enhanced angiogenesis and scar tissue reduction

Wolverine Blend (TB-500 + BPC-157) in Research: Study Context

The Wolverine Blend is a dual-peptide research formulation combining BPC-157 (a stable gastric pentadecapeptide studied for angiogenesis and tendon/muscle/GI repair through VEGF/FGF upregulation and the NO system) and TB-500/thymosin beta-4 (the major actin-sequestering peptide, studied for cell migration, re-epithelialization, angiogenesis, and anti-inflammatory/anti-fibrotic activity). Each peptide has an extensive individual preclinical literature, but the combined BPC-157/TB-500 stack has not been separately characterized in controlled human trials, so the rationale for combining complementary repair pathways is inferred from single-component studies. For laboratory use the lyophilized powder is reconstituted with bacteriostatic water to a defined concentration (e.g. a 20 mg 1:1 vial in 2 mL yields 10.0 mg/mL) strictly for in-vitro/research handling - this is not an FDA-approved product and no human concentration is implied. Researchers should reference the primary BPC-157 and thymosin beta-4 literature and document the lot-specific Certificate of Analysis (HPLC purity, mass-spec identity).

How Wolverine Blend (TB-500 + BPC-157) Compares

Researchers frequently evaluate Wolverine Blend (TB-500 + BPC-157) alongside related compounds:

Wolverine Blend (TB-500 + BPC-157) — Frequently Asked Questions

What are the two components of the Wolverine Blend and what is each studied for?
The blend contains BPC-157 (studied in animal models for angiogenesis and tendon/muscle/GI tissue repair via VEGF/FGF and NO-system modulation) and TB-500/thymosin beta-4 (an actin-sequestering peptide studied for cell migration, re-epithelialization, and anti-fibrotic activity). They are combined at a 1:1 ratio to study complementary repair pathways in a single reconstitution.
Has the BPC-157 + TB-500 combination been studied as a blend?
No controlled clinical trials have characterized the specific combination. Both peptides have substantial individual preclinical literature, and the rationale for stacking them (localized angiogenesis from BPC-157 plus systemic cell migration from TB-500) is extrapolated from those single-component studies rather than from combined-formulation trials.
What documentation should accompany a Wolverine Blend research lot?
Each lot should ship with a Certificate of Analysis confirming HPLC purity and mass-spectrometry identity for the constituent peptides. Researchers should design assays from the primary BPC-157 and thymosin beta-4 literature rather than from combined-formulation claims.
Is Wolverine Blend (TB-500 + BPC-157) legal to buy for research?
Wolverine Blend (TB-500 + BPC-157) is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does Wolverine Blend (TB-500 + BPC-157) come with a Certificate of Analysis?
Yes. Every batch of Wolverine Blend (TB-500 + BPC-157) from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is the Wolverine Stack and how does it work?
The Wolverine Stack is a dual-peptide formulation combining BPC-157 and TB-500 in a single vial. BPC-157 promotes tissue repair through nitric oxide system modulation and growth factor upregulation, while TB-500 facilitates healing through actin sequestration and cell migration. Together, these peptides target complementary repair pathways — allowing researchers to study synergistic tissue regeneration mechanisms in a single reconstitution.
What research supports the BPC-157 and TB-500 combination?
While the specific combination has not been the subject of large-scale clinical trials, both individual peptides have extensive preclinical research. BPC-157 has over 100 published studies demonstrating tissue repair across multiple organ systems. TB-500 research (Annals of the New York Academy of Sciences, FASEB Journal) has shown cardiac and dermal repair activity. The complementary mechanisms (NO system vs. actin dynamics) provide a scientific rationale for combination research.
How does the Wolverine Stack compare to using BPC-157 and TB-500 separately?
The Wolverine Stack offers the convenience of a pre-combined formulation at a 1:1 ratio (10mg BPC-157 + 10mg TB-500), eliminating the need for separate reconstitutions and calculations. Researchers studying combined studies benefit from consistent ratios and reduced preparation time. Purchasing individual vials offers more flexibility for studies requiring different ratios or independent schedules.

Research References

  1. Chang CH, et al. Pentadecapeptide BPC 157 promotes tendon healing and modulates angiogenesis (VEGF) in muscle and tendon healing. J Appl Physiol. 2011.
  2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005.
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.